Niclosamide has been shown to be anti-proliferative against prostate, colorectal, lung, breast, and ovarian cancers, and myelogenous leukemia by inhibiting multiple pathways (Wnt/β-catenin, Notch, NF-kB, mTOR, and STAT3) and inducing mitochondrial uncoupling [13, 16, 25–33]. Here, STAT3 is linked to myeloid leukemia.